Colorectal Cancer Clinical Trial
Official title:
Irinotecan and 5-Fluorouracil/Leucovorin for Patients With Colorectal Carcinoma and Other Refractory Tumors
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin,
work in different ways to stop tumor cells from dividing so they stop growing or die.
Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one
chemotherapy drug with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
with radiation therapy works in treating patients with stage III or stage IV colorectal
carcinoma (cancer), other refractory carcinoma (cancer), or metastatic adenocarcinoma
(cancer) of unknown primary origin.
OBJECTIVES:
- Determine the response rate in patients with stage IV colorectal carcinoma or other
carcinomas treated with irinotecan followed by fluorouracil and leucovorin calcium.
- Determine the disease-free survival of patients with stage III colorectal carcinoma,
other refractory carcinomas, or metastatic adenocarcinomas of unknown primary site
treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Patients with stage III colorectal carcinoma (post surgical resection) receive
irinotecan IV over 1 hour on days 1-5 and days 8-12. Treatment repeats every 3 weeks for 2
courses. Beginning on week 7, patients receive pelvic irradiation, leucovorin calcium IV
over 4 hours, and fluorouracil IV over 5-15 minutes beginning 1 hour into leucovorin calcium
infusion on days 1-5. Treatment repeats every 3 weeks for a total of 2 courses. Patients
with no evidence of disease may repeat the above 12-week block of chemotherapy without
pelvic irradiation up to 4 times over 1 year.
Patients with stage IV colorectal carcinoma, other refractory carcinomas, or metastatic
adenocarcinomas of unknown primary site receive the above 12-week block of chemotherapy
(irinotecan, fluorouracil, and leucovorin calcium) with pelvic irradiation (if indicated).
Pelvic irradiation patients with an unresected primary tumor undergo exploratory surgery 4-5
weeks after completion of radiotherapy, even in the absence of visible tumor regression.
Radical resection is attempted to effect local control and control of long term symptoms
related to the primary tumor. Patients with complete response (CR) or partial response (PR)
after both chemotherapy and surgery repeat the above 12-week block of chemotherapy 3 times
over 1 year in the absence of disease progression or unacceptable toxicity. Patients with CR
or PR after chemotherapy but no response after surgery receive irinotecan IV over 1 hour on
days 1-5 and days 8-12 every 3 weeks for 1 year in the absence of disease progression or
unacceptable toxicity. Patients with stable disease (SD) or progressive disease after 2
courses of irinotecan and SD, CR, or PR after surgery receive leucovorin calcium and
fluorouracil as above every 3 weeks for 1 year in the absence of disease progression or
unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 4 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |